IGATE CORPORATION Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2015-03-31..
- Stock-based compensation / revenue · 12 months: Value 1.36%; Formula and calculation Share-based compensation / revenue. Period ending 2015-03-31..
- Interest coverage · 12 months: Value 6.36×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2015-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2015-03-31. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.36% | Share-based compensation / revenue. Period ending 2015-03-31. $17.47M ÷ $1.29B × 100 ≈ 1.36% |
| Interest coverage · 12 months | 6.36× | Operating income ÷ reported interest expense. $214.13M ÷ $33.67M ≈ 6.36× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 1.29B USD | |
| Stock-based compensation | 17.47M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 214.13M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 33.67M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2015-03-31 | (m) | $1.29B | $17.47M | $214.13M | $33.67M | (m) | 1.36% | 6.36× | Reported |
| 2014-12-31 | (m) | $1.27B | $17.38M | $220.42M | $49.91M | (m) | 1.37% | 4.42× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $1.18B | $13.01M | $235.83M | $88.55M | (m) | 1.10% | 2.66× | Reported |
| 2013-12-31 | (m) | $1.15B | $11.84M | $227.24M | $87.58M | (m) | 1.03% | 2.59× | Reported |
| 2013-09-30 | (m) | $1.12B | $10.24M | $224.61M | $88.64M | (m) | 0.91% | 2.53× | Reported |
| 2013-06-30 | (m) | $1.10B | $10.16M | $212.30M | $90.38M | (m) | 0.92% | 2.35× | Reported |
| 2013-03-31 | (m) | (m) | $12.59M | (m) | $87.30M | (m) | (m) | (m) | Reported |
| 2012-12-31 | (m) | $1.07B | $12.27M | $206.27M | $83.77M | (m) | 1.14% | 2.46× | Reported |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $779.65M | $10.74M | $105.91M | $50.61M | (m) | 1.38% | 2.09× | Reported |
| 2011-09-30 | (m) | $592.95M | $10.70M | $69.80M | $32.86M | (m) | 1.80% | 2.12× | Reported |
| 2011-06-30 | (m) | $402.07M | $8.18M | $47.22M | $13.36M | (m) | 2.03% | 3.53× | Reported |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $280.60M | $6.65M | $53.01M | $108.00K | (m) | 2.37% | 490.81× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $193.10M | $5.15M | $32.39M | $69.00K | (m) | 2.67% | 469.43× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.